Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Endocrinology · Primary Aldosteronism

Life After Treatment: The Road to Recovery

At a Glance

Recovery from primary aldosteronism is a gradual process where the body heals from excess aldosterone. While heart damage and mental health often improve, kidney lab numbers may initially drop as the kidneys stop overworking. Long-term monitoring of renin, potassium, and blood pressure is essential.

Finding the right treatment for Primary Aldosteronism (PA) is a major milestone, but it is not the end of the journey. Once your hormones are under control—whether through surgery or medication—your body begins a “remodeling” phase that can take months or even years [1]. Understanding this long-term phase is key to ensuring your heart and kidneys stay healthy for the rest of your life.

Reversing the Damage: The Heart and Vessels

Excess aldosterone is toxic to the heart, often causing the heart muscle to become dangerously thick (left ventricular hypertrophy or LVH) [2]. The good news is that both surgery and medication (MRAs) can reverse this damage [1].

  • Surgery (Adrenalectomy): This typically offers the most complete and rapid reversal of heart thickening and arterial stiffness [3][4].
  • Medical Management: While highly effective, medical therapy requires precise dosing. If your dose is too low and your renin levels stay “suppressed” (very low), your heart remains at higher risk for damage [5][6].

The “Kidney Reset”

One of the most common surprises for patients after treatment is a sudden drop in their kidney function numbers, specifically their eGFR (estimated glomerular filtration rate) [7].

This is usually not a sign of new kidney damage. For years, the excess aldosterone forced your kidneys to work at “110% capacity”—a state called hyperfiltration [8]. Once the hormone is blocked or removed, your kidneys finally “relax” and return to a normal workload [8]. While the numbers on the lab report might look worse, your kidneys are actually healthier and more protected from long-term failure [9][10].

Life After Treatment: Quality of Life

PA takes a significant toll on mental health, often causing “brain fog,” chronic fatigue, and high levels of anxiety and depression [11].

  • The Rebound: Research shows that most patients experience a dramatic improvement in their quality of life after treatment [12][13].
  • Mood Shifts: Interestingly, some studies show that surgery is particularly effective at improving depressive symptoms, while medication (MRAs) can be very helpful for reducing anxiety [14][15].

Your Long-Term Monitoring Plan

Regardless of which treatment you received, you will need ongoing surveillance, especially in the first year:

  • Electrolyte Checks: Your doctor will monitor your potassium levels closely. If you had surgery, your remaining adrenal gland may take a few weeks to “wake up,” and you may temporarily need extra salt or a medication called fludrocortisone [16][17].
  • The Renin Goal: If you are on medication, your doctor should adjust your dose until your renin is no longer suppressed. Normalizing renin is the best way to prove that the “aldosterone shield” is working [5][18].
  • Blood Pressure Logs: You should continue to monitor your blood pressure at home. Even if you are “cured,” your blood pressure may continue to improve for up to a year as your blood vessels heal [13].

Living with PA is a marathon, not a sprint. By staying engaged with your medical team and understanding these long-term “remodeling” processes, you can move forward with confidence, knowing you have significantly lowered your risk of stroke, heart failure, and kidney disease [19][20].

Common questions in this guide

What happens to my kidney function after treating primary aldosteronism?
It is common to see a drop in your estimated glomerular filtration rate (eGFR) after treatment. This usually means your kidneys are relaxing from being overworked by excess aldosterone, rather than indicating new kidney damage.
Will treatment for primary aldosteronism improve my mental health?
Yes, many patients experience a significant improvement in quality of life after treatment. You may notice a decrease in brain fog, chronic fatigue, anxiety, and depression as your hormones stabilize.
What should my target renin level be if I am taking medication?
If you manage the condition with medication, your doctor will adjust your dose until your renin levels are no longer suppressed. Normalizing your renin is the best indicator that your medication is effectively blocking the excess aldosterone.
Can the heart damage from primary aldosteronism be reversed?
Yes, the thickening of the heart muscle caused by excess aldosterone can often be reversed. Both surgical removal of the adrenal gland and medical management can help your heart heal and reduce arterial stiffness over time.
Will I need hormone replacement after adrenal surgery?
Your remaining adrenal gland may take a few weeks to fully function after surgery. During this time, your doctor will closely monitor your potassium levels and may temporarily prescribe extra salt or a medication called fludrocortisone.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my target renin level, and how often will we test it to ensure my medication dose is optimal?
  2. 2.Should we perform a follow-up echocardiogram to see if my heart muscle thickening (LVH) has started to reverse?
  3. 3.How will we monitor my kidney function (eGFR) in the coming months, and what drop in numbers would be considered 'normal'?
  4. 4.If I had surgery, do I need any short-term hormone replacement (like fludrocortisone) while my remaining adrenal gland 'wakes up'?
  5. 5.Are there specific resources or support groups for patients managing the mental health impacts of primary aldosteronism?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy.

    Adolf C, Köhler A, Franke A, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(12)):4543-4552 doi:10.1210/jc.2018-00617.

    PMID: 30113683
  2. 2

    Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study.

    Brown JM, Wijkman MO, Claggett BL, et al.

    Hypertension (Dallas, Tex. : 1979) 2022; (79(9)):1984-1993 doi:10.1161/HYPERTENSIONAHA.122.19134.

    PMID: 35582954
  3. 3

    Adrenalectomy Versus Medical Therapy in Primary Aldosteronism: A Meta-Analysis of Long-Term Cardiac Remodeling and Function: Medical versus Adrenalectomy Treatment Compared in Hyperaldosteronism (MATCH) Study.

    Marzano L, Zoccatelli F, Pizzolo F, Friso S

    Hypertension (Dallas, Tex. : 1979) 2025; (82(8)):e142-e153 doi:10.1161/HYPERTENSIONAHA.125.25104.

    PMID: 40557482
  4. 4

    Reversal of arterial stiffness in medically and surgically treated unilateral primary aldosteronism.

    Chen ZW, Liao CW, Pan CT, et al.

    Journal of hypertension 2024; (42(3)):538-545 doi:10.1097/HJH.0000000000003631.

    PMID: 38088428
  5. 5

    Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.

    Katsuragawa S, Goto A, Shinoda S, et al.

    Hypertension (Dallas, Tex. : 1979) 2023; (80(9)):1909-1920 doi:10.1161/HYPERTENSIONAHA.123.21096.

    PMID: 37449450
  6. 6

    Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta-Analysis.

    Huang CW, Huang TY, Yang YF, et al.

    Journal of the American Heart Association 2025; (14(3)):e038714 doi:10.1161/JAHA.124.038714.

    PMID: 39895534
  7. 7

    Renal function after adrenalectomy in patients with primary aldosteronism.

    Stahl KA, Ramonell KM, Puli A, et al.

    Surgery 2026; (189()):109761 doi:10.1016/j.surg.2025.109761.

    PMID: 41046237
  8. 8

    Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

    Wu VC, Chan CK, Chueh JS, et al.

    Journal of the American Heart Association 2023; (12(4)):e028146 doi:10.1161/JAHA.122.028146.

    PMID: 36789834
  9. 9

    Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.

    Hundemer GL, Curhan GC, Yozamp N, et al.

    Hypertension (Dallas, Tex. : 1979) 2018; (72(3)):658-666 doi:10.1161/HYPERTENSIONAHA.118.11568.

    PMID: 29987110
  10. 10

    Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry.

    Araujo-Castro M, Paja Fano M, González-Boillos M, et al.

    Journal of hypertension 2024; (42(10)):1805-1812 doi:10.1097/HJH.0000000000003813.

    PMID: 39051487
  11. 11

    Health-Related Quality of Life and Mental Health in Primary Aldosteronism: A Systematic Review.

    Velema MS, de Nooijer AH, Burgers VWG, et al.

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017; (49(12)):943-950 doi:10.1055/s-0043-121706.

    PMID: 29202493
  12. 12

    Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study.

    Tan YK, Kwan YH, Teo DCL, et al.

    Endocrine connections 2021; (10(8)):834-844.

    PMID: 34223820
  13. 13

    Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism.

    Citton M, Viel G, Torresan F, et al.

    BMC surgery 2019; (18(Suppl 1)):105 doi:10.1186/s12893-018-0432-1.

    PMID: 31074381
  14. 14

    Differential central regulatory mineralocorticoidreceptor systems for anxiety and depression - Could KCNJ5 be an interesting target for further investigations in major depression?

    Adolf C, Murck H, Sarkis AL, et al.

    Journal of psychiatric research 2022; (156()):69-77 doi:10.1016/j.jpsychires.2022.09.008.

    PMID: 36242946
  15. 15

    Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety.

    Murck H, Adolf C, Schneider A, et al.

    Journal of psychiatric research 2021; (137()):376-382 doi:10.1016/j.jpsychires.2021.02.064.

    PMID: 33761426
  16. 16

    Persistent severe hyperkalemia following surgical treatment of aldosterone-producing adenoma.

    Preda C, Teodoriu LC, Placinta S, et al.

    Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2020; (25()):17 doi:10.4103/jrms.JRMS_603_19.

    PMID: 32174989
  17. 17

    The Lingering Battle of Persistent Hypoaldosteronism Following Adrenalectomy for Primary Aldosteronism: A Case Report.

    En Tan J, Merican NSYA, Ismail S, Abdullah NRA

    Journal of the ASEAN Federation of Endocrine Societies 2026; (41(1)):198-203 doi:10.15605/jafes.041.01.5151.

    PMID: 42311542
  18. 18

    Predictors of treatment response to mineralocorticoid receptor antagonists in primary aldosteronism: insights from the SPAIN-ALDO registry.

    Goi J, Paja Fano M, Rizo Gellida A, et al.

    Journal of hypertension 2026; (44(9)):1530-1538 doi:10.1097/HJH.0000000000004365.

    PMID: 42267552
  19. 19

    Aldosterone as a Mediator of Cardiovascular Damage.

    Buffolo F, Tetti M, Mulatero P, Monticone S

    Hypertension (Dallas, Tex. : 1979) 2022; (79(9)):1899-1911 doi:10.1161/HYPERTENSIONAHA.122.17964.

    PMID: 35766038
  20. 20

    Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis.

    Chen SY, Chen JY, Huang WC, et al.

    European journal of endocrinology 2022; (187(6)):S47-S58 doi:10.1530/EJE-22-0375.

    PMID: 36315466

This page provides educational information about recovering from primary aldosteronism treatment. It does not replace professional medical advice. Always consult your endocrinologist or care team about your specific monitoring and recovery plan.

Get notified when new evidence is published on hyperaldosteronism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.